BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36003795)

  • 21. Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients.
    Zhang W; Dun J; Li H; Liu J; Chen H; Yu H; Xu J; Zhou F; Qiu Y; Hao J; Hu Q; Wu X
    Hematology; 2023 Dec; 28(1):2231731. PubMed ID: 37522469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute Megakaryoblastic Leukemia with Trisomy 21 and Tetrasomy 21 Clones in a Phenotypically Normal Child with Mosaic Trisomy 21.
    Won E; Gruber TA; Tucker S; Schiff DE
    Case Rep Pediatr; 2020; 2020():7813048. PubMed ID: 32257492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
    Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target cell of leukemic transformation in acute megakaryoblastic leukemia.
    Koike T; Urushiyama M; Narita M; Saitoh H; Ishida F; Imashuku S; Morioka Y; Utsumi J; Ishizuka T; Tsuruta T
    Am J Hematol; 1990 Aug; 34(4):252-8. PubMed ID: 2164321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern.
    de Rooij JD; Hollink IH; Arentsen-Peters ST; van Galen JF; Berna Beverloo H; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Zimmermann M; Alonzo TA; Pieters R; Meshinchi S; van den Heuvel-Eibrink MM; Zwaan CM
    Leukemia; 2013 Dec; 27(12):2280-8. PubMed ID: 23531517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
    Savaşan S; Buck S; Raimondi SC; Becton DL; Weinstein H; Chang M; Ravindranath Y
    Leuk Lymphoma; 2006 Oct; 47(10):2076-83. PubMed ID: 17071479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.
    Gruber TA; Larson Gedman A; Zhang J; Koss CS; Marada S; Ta HQ; Chen SC; Su X; Ogden SK; Dang J; Wu G; Gupta V; Andersson AK; Pounds S; Shi L; Easton J; Barbato MI; Mulder HL; Manne J; Wang J; Rusch M; Ranade S; Ganti R; Parker M; Ma J; Radtke I; Ding L; Cazzaniga G; Biondi A; Kornblau SM; Ravandi F; Kantarjian H; Nimer SD; Döhner K; Döhner H; Ley TJ; Ballerini P; Shurtleff S; Tomizawa D; Adachi S; Hayashi Y; Tawa A; Shih LY; Liang DC; Rubnitz JE; Pui CH; Mardis ER; Wilson RK; Downing JR
    Cancer Cell; 2012 Nov; 22(5):683-97. PubMed ID: 23153540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
    Xavier AC; Ge Y; Taub JW
    J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia.
    Takeda A; Shimada A; Hamamoto K; Yoshino S; Nagai T; Fujii Y; Yamada M; Nakamura Y; Watanabe T; Watanabe Y; Yamamoto Y; Sakakibara K; Oda M; Morishima T
    Acta Med Okayama; 2014; 68(2):119-23. PubMed ID: 24743787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute megakaryoblastic leukemia with trisomy 3 and CBFA2T3::GLIS2: A case report.
    Gillam J; Catic A; Paulraj P; Dalton J; Lai G; Jackson-Cook C; Turner S; Ferreira-Gonzalez A; Barrie E
    Genes Chromosomes Cancer; 2022 Aug; 61(8):491-496. PubMed ID: 35294081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model.
    Hack T; Bertram S; Blair H; Börger V; Büsche G; Denson L; Fruth E; Giebel B; Heidenreich O; Klein-Hitpass L; Kollipara L; Sendker S; Sickmann A; Walter C; von Neuhoff N; Hanenberg H; Reinhardt D; Schneider M; Rasche M
    Mol Cancer Res; 2020 Oct; 18(10):1603-1612. PubMed ID: 32641517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
    Masetti R; Bertuccio SN; Pession A; Locatelli F
    Br J Haematol; 2019 Feb; 184(3):337-347. PubMed ID: 30592296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
    Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
    Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
    McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
    Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New hPSC-based human models to study pediatric Acute Megakaryoblastic Leukemia harboring the fusion oncogene RBM15-MKL1.
    Ayllón V; Vogel-González M; González-Pozas F; Domingo-Reinés J; Montes R; Morales-Cacho L; Ramos-Mejía V
    Stem Cell Res; 2017 Mar; 19():1-5. PubMed ID: 28412998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina.
    Pennella CL; Cassina TM; Rossi JG; Baialardo EM; Rubio P; Deu MA; Peruzzo L; Guitter MR; Sanchez de La Rosa CG; Alfaro EM; Felice MS
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.